Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Share-based Compensation (IS) (2022 - 2024)

Historic Share-based Compensation (IS) for Indivior Pharmaceuticals (INDV) over the last 3 years, with Q4 2024 value amounting to $6.0 million.

  • Indivior Pharmaceuticals' Share-based Compensation (IS) changed 0.0% to $6.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $24.0 million, marking a year-over-year increase of 909.09%. This contributed to the annual value of $24.0 million for FY2024, which is 909.09% up from last year.
  • As of Q4 2024, Indivior Pharmaceuticals' Share-based Compensation (IS) stood at $6.0 million, which was down 0.0% from $7.0 million recorded in Q3 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' Share-based Compensation (IS) peaked at $7.0 million during Q3 2024, and registered a low of $4.0 million during Q4 2022.
  • For the 3-year period, Indivior Pharmaceuticals' Share-based Compensation (IS) averaged around $5.5 million, with its median value being $5.5 million (2022).
  • Over the last 5 years, Indivior Pharmaceuticals' Share-based Compensation (IS) had its largest YoY gain of 5000.0% in 2023, and its largest YoY loss of 0.0% in 2023.
  • Indivior Pharmaceuticals' Share-based Compensation (IS) (Quarter) stood at $4.0 million in 2022, then surged by 50.0% to $6.0 million in 2023, then changed by 0.0% to $6.0 million in 2024.
  • Its Share-based Compensation (IS) was $6.0 million in Q4 2024, compared to $7.0 million in Q3 2024 and $6.0 million in Q2 2024.